Phase 3 EIN Clinical Trials
28 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 28 trials
Recruiting
Phase 2Phase 3
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
Proteinuric Kidney Disease
Vertex Pharmaceuticals Incorporated466 enrolled318 locationsNCT05312879
Recruiting
Phase 3
Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
Myotonic DystrophyDM1Steinert Disease+2 more
Dyne Therapeutics150 enrolled4 locationsNCT07486934
Recruiting
Phase 3
A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria
Chronic Kidney DiseaseProteinuria
Bayer219 enrolled164 locationsNCT05196035
Recruiting
Phase 3
A Study to Learn More About How Safe the Study Treatment Finerenone is in Long-term Use When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker Over 18 Months of Use in Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria
Chronic Kidney DiseaseProteinuriaChildren
Bayer100 enrolled178 locationsNCT05457283
Recruiting
Phase 3
A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Hoffmann-La Roche152 enrolled82 locationsNCT05271409
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled72 locationsNCT07517263
Recruiting
Phase 3
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
AMLRUNX1-RUNX1T1 Fusion Protein Expression
Institute of Hematology & Blood Diseases Hospital, China300 enrolled1 locationNCT06744504
Recruiting
Phase 3
Study of Ravulizumab in Pediatric Participants With Primary IgAN
Immunoglobulin A NephropathyIgANIgA Vasculitis+3 more
Alexion Pharmaceuticals, Inc.24 enrolled14 locationsNCT07024563
Recruiting
Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)Solid Organ Transplant ComplicationsLymphoproliferative Disorders+2 more
Pierre Fabre Medicament115 enrolled71 locationsNCT03394365
Recruiting
Phase 3
Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
Autoimmune Pulmonary Alveolar Proteinosis
Savara Inc.5 enrolled1 locationNCT06431776
Recruiting
Phase 3
Empagliflozin Addition in Modulating Metabolic Disturbances Associated With Olanzapine in Schizophrenia Patients
Sodium-glucose Transport Protein Two Inhibitor (SGLT2),Metabolic Deficits Caused by Antipsychotics
Tanta University40 enrolled1 locationNCT05669742
Recruiting
Phase 3
RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing
Venous ThromboembolismPulmonary EmbolismDeep Vein Thrombosis+3 more
University Hospital, Angers1,424 enrolled35 locationsNCT06195540
Recruiting
Phase 3
Evaluation of the Efficacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's Disease)
MetforminMyotonic Dystrophy 1Steinert's Disease
Assistance Publique - Hôpitaux de Paris142 enrolled1 locationNCT05532813
Recruiting
Phase 2Phase 3
A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg
ThrombosisSuperficial Vein ThrombosisSVT
Ottawa Hospital Research Institute50 enrolled2 locationsNCT06965998
Recruiting
Phase 3
Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors.
Luteinised Follicular Cyst
IVI Madrid152 enrolled1 locationNCT06244745
Recruiting
Phase 3
Combination of Ranibizumab and Targeted Laser Photocoagulation
Central Retinal Vein Occlusion With Macular Edema
University of Giessen110 enrolled15 locationsNCT04444492
Recruiting
Phase 2Phase 3
Unravelling Intestinal Fibrosis in Ulcerative Colitis
Fibroblast Activation Protein InhibitorUlcerative Colitis (UC)Inflammatory Bowel Disease (IBD)
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)10 enrolled1 locationNCT06604273
Not Yet Recruiting
Phase 3
Efficacy of Reducing Fatigue In Relapsing Multiple Sclerosis: An Epstein Barr Virus Treatment Trial (FIRMS EBV)
Multiple SclerosisEpstein Barr Virus
The University of Sydney240 enrolled12 locationsACTRN12624000423516
Completed
Phase 3
Effect of topical and oral Resveratrol on skin health, condition and visible signs of ageing, in healthy ageing females.
Skin healthVisible signs of skin ageingSkin condition - pores, sebum, wrinkle, pigment condition, moisture, elasticity, skin tone
and skin temperature
RDC Clinical Pty Ltd140 enrolled1 locationACTRN12621000709842
Active
Phase 3Phase 4
Investigation of the Effects of Longvida Curcumin on Cognitive Function, Mood and Biomarkers of Health.
Brain function (fMRI)Psychological wellbeing (mood, stress fatigue, sleep)Inflammation+2 more
Swinburne University of Technology, Centre for Human Psychopharmacology80 enrolled1 locationACTRN12616000484448